157 related articles for article (PubMed ID: 35903249)
1. In Vivo Distribution and Therapeutic Efficacy of Radioiodine-Labeled pH-Low Insertion Peptide Variant 3 in a Mouse Model of Breast Cancer.
Zhang M; Xi Y; Chen H; Hai W; Li B
Mol Imaging; 2022; 2022():7456365. PubMed ID: 35903249
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Radioiodine-Labeled pH (Low) Insertion Peptide Variant 7-Like Peptide as a Noninvasive Tumor Microenvironment Imaging Agent in a Mouse MDA-MB-231 Triple-Negative Breast Cancer Model.
Wu F; Chen Y; Li D; Wang Z; Yu M
Mol Imaging Biol; 2022 Aug; 24(4):570-579. PubMed ID: 35006491
[TBL] [Abstract][Full Text] [Related]
3. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
Yu M; Chen Y; Wang Z; Ding X
Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MDA-MB-231 cell proliferation by pHLIP(Var7)-P1AP and SPECT imaging of MDA-MB-231 breast cancer-bearing nude mice using 125I-pHLIP(Var7)-P1AP.
Chen YH; Yu MM; Wang ZG
Nuklearmedizin; 2021 Jun; 60(3):240-248. PubMed ID: 33759146
[TBL] [Abstract][Full Text] [Related]
5. The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions.
Tapmeier TT; Moshnikova A; Beech J; Allen D; Kinchesh P; Smart S; Harris A; McIntyre A; Engelman DM; Andreev OA; Reshetnyak YK; Muschel RJ
Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9710-5. PubMed ID: 26195776
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of Technetium-99m-Labeled pH (Low) Insertion Peptide Variant 7 for Early Diagnosis of MDA-MB-231 Triple-Negative Breast Cancer by Targeting the Tumor Microenvironment.
Chen Y; Su Y; Pang X; Song X; Zhao W; Yu M
Front Oncol; 2022; 12():869260. PubMed ID: 35530359
[TBL] [Abstract][Full Text] [Related]
7. Targeting breast tumors with pH (low) insertion peptides.
Adochite RC; Moshnikova A; Carlin SD; Guerrieri RA; Andreev OA; Lewis JS; Reshetnyak YK
Mol Pharm; 2014 Aug; 11(8):2896-905. PubMed ID: 25004202
[TBL] [Abstract][Full Text] [Related]
8. An Experimental Study on [
Yu M; Sun Y; Yang G; Wang Z
Mol Imaging; 2021; 2021():5565932. PubMed ID: 33746628
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: A Structure-Activity Optimization Study.
Demoin DW; Wyatt LC; Edwards KJ; Abdel-Atti D; Sarparanta M; Pourat J; Longo VA; Carlin SD; Engelman DM; Andreev OA; Reshetnyak YK; Viola-Villegas N; Lewis JS
Bioconjug Chem; 2016 Sep; 27(9):2014-23. PubMed ID: 27396694
[TBL] [Abstract][Full Text] [Related]
10. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
11. Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors.
Wyatt LC; Moshnikova A; Crawford T; Engelman DM; Andreev OA; Reshetnyak YK
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2811-E2818. PubMed ID: 29507241
[TBL] [Abstract][Full Text] [Related]
12. Ex-vivo Imaging of Upper Tract Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a Molecular Imaging Probe.
Brito J; Golijanin B; Kott O; Moshnikova A; Mueller-Leonhard C; Gershman B; Andreev OA; Reshetnyak YK; Amin A; Golijanin D
Urology; 2020 May; 139():134-140. PubMed ID: 30659902
[TBL] [Abstract][Full Text] [Related]
13. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
14. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
15.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
16. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
17. Multiplexed Imaging Reveals the Spatial Relationship of the Extracellular Acidity-Targeting pHLIP with Necrosis, Hypoxia, and the Integrin-Targeting cRGD Peptide.
Jin ZH; Tsuji AB; Degardin M; Dumy P; Boturyn D; Higashi T
Cells; 2022 Nov; 11(21):. PubMed ID: 36359894
[TBL] [Abstract][Full Text] [Related]
18. Smart Design of a pH-Responsive System Based on pHLIP-Modified Magnetite Nanoparticles for Tumor MRI.
Demin AM; Pershina AG; Minin AS; Brikunova OY; Murzakaev AM; Perekucha NA; Romashchenko AV; Shevelev OB; Uimin MA; Byzov IV; Malkeyeva D; Kiseleva E; Efimova LV; Vtorushin SV; Ogorodova LM; Krasnov VP
ACS Appl Mater Interfaces; 2021 Aug; 13(31):36800-36815. PubMed ID: 34324807
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
